Slingshot Bio Taps Sales Vet to Drive Global Synthetic Cell Dominance

EMERYVILLE, Calif. – March 05, 2026 – Slingshot Biosciences, a company at the forefront of synthetic cell technology, has appointed life sciences veteran Jim Snook as its Senior Vice President of Global Sales. The strategic move signals an aggressive push to accelerate the global adoption of its cell mimic platform, particularly as the demand for precision and reproducibility skyrockets in the fields of clinical diagnostics and cell therapy.

Snook will now helm Slingshot's entire global sales apparatus, a role that encompasses business development, inside sales, distribution management, and the crucial field application scientist teams. His appointment comes at a time when the company, backed by $46.4 million in funding, is rapidly expanding its commercial footprint through new distribution agreements and direct market entry.

A Veteran to Steer Aggressive Expansion

Jim Snook is not new to the challenge of scaling commercial operations in the competitive life sciences arena. He brings over two decades of executive leadership, most recently from Bio-Techne, where he served as Vice President, Commercial for the Protein Sciences business unit. There, he was credited with leading a transformation of the sales organization to capture market share and drive growth. Before that, Snook headed the Americas commercial team at Miltenyi Biotec, a period during which the organization cemented its status as a market leader in cell and gene therapy solutions.

This track record is precisely what Slingshot's leadership was seeking. "Jim's appointment marks a pivotal moment for Slingshot Biosciences as we accelerate our global growth," said Glenn Bilawsky, Chief Executive Officer of Slingshot Biosciences. "His proven track record of building high-performing sales organizations and driving substantial revenue growth at leading life sciences companies makes him the ideal leader to take our commercial efforts to the next level. Jim's deep understanding of the flow cytometry and cell therapy markets, combined with his expertise in scaling sales operations, will be instrumental in expanding our reach and serving our customers worldwide."

This strategic hire builds on a period of significant momentum for the company. Following an $11 million Series A3 financing round in early 2023, Slingshot has inked distribution deals across Europe and Asia-Pacific, including with Palex Medical for Spain and Portugal, and Chameleon Science for Australia, New Zealand, and Singapore. The company also recently announced a direct expansion into the United Kingdom and European Union markets, signaling its readiness for large-scale commercial activity.

Solving a Billion-Dollar Reproducibility Problem

At the core of Slingshot's growth strategy is a technology that addresses one of the most persistent challenges in biological research: reproducibility. Flow cytometry, a cornerstone technique for analyzing cells, has long been plagued by variability. Traditional controls, often derived from human or animal cells, suffer from donor-to-donor and lot-to-lot inconsistencies, creating unreliable data and costing labs significant time and money in failed experiments.

Slingshot bypasses these biological limitations entirely. The company's patented platform uses a unique combination of advanced polymer chemistry and the kind of precision found in semiconductor manufacturing to create synthetic cell mimics. These mimics, such as the company's flagship TruCytes™, are engineered to replicate the specific optical and biochemical properties of target cells—from T-cells to cancer cells—without any of the inherent variability of biological material. The result is a control that is stable over long periods, highly reproducible, and ultimately more cost-effective.

The impact is already being felt in labs. Research partners like the Fred Hutch Cancer Center have reported significant improvements in assay reliability after integrating Slingshot’s mimics. This ability to provide a consistent, reliable standard is critical for everything from basic research to the development of complex, multi-parameter clinical assays.

Capitalizing on the Cell Therapy Revolution

Perhaps the most significant opportunity for Slingshot's technology lies within the booming cell and gene therapy sector. This market, projected to grow at a compound annual growth rate (CAGR) of over 20%, depends on stringent quality control (QC) to ensure the safety and efficacy of living medicines. The manufacturing process for therapies like CAR-T cells is notoriously complex, and ensuring that each batch meets release criteria is a major regulatory and logistical hurdle.

Slingshot is positioning its technology as an indispensable tool for industrializing cell therapy manufacturing. A landmark collaboration announced in late 2025 with Cellares, an Integrated Development and Manufacturing Organization (IDMO), exemplifies this strategy. The partnership integrates Slingshot's TruCytes™ Biomarker controls directly into Cellares' Cell Q™ platform, an automated quality-control system. This move aims to deliver continuous, reliable testing at an industrial scale, reducing QC failure rates, improving comparability between manufacturing runs, and lowering operational costs for therapy developers.

The synthetic mimics provide a stable reference standard that automated systems can rely on, removing the human variability and logistical challenges of using live cells for daily QC. As the cell therapy market matures and moves toward greater automation and scale, such enabling technologies become essential components of the manufacturing ecosystem.

For his part, Snook is ready to champion this technological shift. "I'm thrilled to join Slingshot Biosciences at such an exciting time in the company's growth," he stated. "The platform represents a genuine breakthrough in addressing many of the challenges in complex cell analysis from robust assay development through scalable deployment. Slingshot has developed an enabling solution for the flow cytometry community, and our consultative team looks forward to bringing this technology to researchers, labs and manufacturers around the globe."